EMD Millipore collaborates with Turgut Ilac on biosimilars

EMD Millipore, the Life Science business of Germany’s Merck KGaA (MRK: DE) has entered into a strategic alliance with Turgut Ilac, a leading biosimilars company based in Turkey and will provide their Provantage End-to-End services for development and manufacturing of biologics.

EMD Millipore's Provantage End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization. The turnkey package includes process development, current Good Manufacturing Practice (cGMP) manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization.

Under this multi-year agreement with family-owned Turgut Ilac, EMD Millipore will provide process development, equipment for a pilot facility, cGMP manufacturing, facility design and ultimately, technology transfer of the manufacturing process to Turgut's facility for commercial production. Use of an identical template in both pilot and commercial scale facilitates technology transfer.